AbCellera Biologics announced an underwritten public offering of $200 million in common shares and pre-funded warrants to fund its internal pipeline, including ABCL635, and general corporate needs. Proceeds will support ongoing research, development and clinical advancement, with Jefferies, J.P. Morgan, Cantor, UBS, and BMO acting as book-running managers. The deal is conditional and not guaranteed to close, pending market conditions.
AbCellera disclosed mid-stage trial data showing a significant reduction in hot flash frequency and severity, boosting ABCL shares about 24% premarket. The result is encouraging but remains early, with durability and replication in larger cohorts key for any further development. Investors should watch for additional readouts and regulatory milestones to gauge longer-term impact on valuation.
Jazz Pharmaceuticals and AbCellera (ABCL) announced a research collaboration and licensing agreement to develop T-cell engaging multispecific antibodies for cancer. The partnership provides external validation of ABCL's platform and could unlock future milestone and royalty revenue if programs progress. In the near term, the impact on ABCL's stock hinges on disclosed terms and pipeline progress.
